Our findings open new avenues for therapeutic intervention in KRAS-mutant cancers, highlighted by the increasing clinical acceptance of therapeutic regimes combining anti-mitotic drugs with other agents for KRAS-mutant lung or pancreatic cancers. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.